Loading…
← CockpitCompetitor Analysis › 300858.SZ Beijing Scitop Bio-Tech Co., Ltd. Class AOpen in the cockpit ↗

Beijing Scitop Bio-Tech Co., Ltd. Class A300858.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 41
Mkt cap
$501M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$5.04M
20-day average traded
Fwd P/E
21.5×
forward earnings
ROIC−WACC
-3.2 pp
WACC 6.9%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥12.66
1D-2.5%
1W-8.5%
1M-10.0%
3M-19.9%
6M-28.3%
YTD-24.5%
1Y-27.7%
ATR %3.9%
52w lowhigh53.2% off high

What Beijing Scitop Bio-Tech does

Employees: 413

Beijing Scitop Bio-Tech at a glance

Size Beijing Scitop Bio-Tech (300858.SZ) is a China Health Care company (Biotechnology) with a market value of $501M, the 3696th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.66 on 18 Nov 2026.

Performance Over six months the shares fell 28.3%, against -5.6% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 18 in its peer set.

Growth Revenue grew 3.9% over the last twelve months (peer median -6.5%); the operating margin is 7.8% (peer median -13.1%).

Valuation It trades at 21.5× forward earnings against a peer median of 17.9× (3rd most expensive of 6).

Capital Return on invested capital runs 3.2 points below its cost of capital (6.9% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 90300858.SZ 73
Six months, rebased to 100: Beijing Scitop Bio-Tech against the median of its 20 peers (local-currency closes).

Beijing Scitop Bio-Tech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥365MCN¥363MCN¥300MCN¥297MCN¥367M
Revenue growth—+21%+1%-19%—
Gross profitCN¥189MCN¥176MCN¥165MCN¥152MCN¥183M
EBITDAn/aCN¥108MCN¥97.4MCN¥85.1MCN¥127M
Net incomeCN¥54.0MCN¥94.5MCN¥94.4MCN¥93.5MCN¥110M
Free cash flow-CN¥28.0M-CN¥173M-CN¥69.4M-CN¥71.2MCN¥64.3M
Capital expenditureCN¥110MCN¥296MCN¥211MCN¥178MCN¥84.2M
Total debtCN¥3.54MCN¥3.59MCN¥3.79MCN¥11.7MCN¥7.70M

Quarterly statements and history in the cockpit →

Beijing Scitop Bio-Tech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%VLA6882476032556586300318CBIO4147MNPRFENC1521DMACWVESTTK041960300858.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Scitop Bio-Tech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×30×603255FENCKMDA1521300858.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Scitop Bio-Tech is the large dot.

Beijing Scitop Bio-Tech competitors and peer comparison

How Beijing Scitop Bio-Tech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Scitop Bio-Tech against its 20 peers (data as of 18 Nov 2026)
Measure300858.SZPeer medianRank in peer set
1-month return-10.0%-12.1%10th highest of 21
6-month return-28.3%-5.6%3rd lowest of 18
Distance from 52-week high-53.2%-44.6%5th lowest of 21
Revenue growth (TTM)+3.9%-6.5%6th highest of 14
Operating margin7.8%-13.1%3rd highest of 14
Forward P/E21.5×17.9×3rd most expensive of 6
ROIC minus cost of capital-3.2 pp-5.5 pp3rd highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%21.5×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%n/an/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%n/a29.4%+7.0%
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%37.5×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%n/an/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%n/an/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%n/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%n/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%16.9×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%17.9×5.0%+6.5%
Frontage 1521.HKHong Kong$542M+113%+10%8%24.6×14.3%+15.4%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%2.3×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%n/an/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%n/an/an/a

Questions

Which companies are Beijing Scitop Bio-Tech's closest peers?
The cockpit's peer set: Valneva (VLA.PA), Sinotherapeutics (688247.SS), LongBio Pharma (Suzhou) (1779.HK), Liaoning Dingjide Petrochemical (603255.SS), CHO Pharma (6586.TWO), Beijing Bohui Innovation Biotechnology (300318.SZ), Crescent Biopharma (CBIO), TaiMed Biologics (4147.TWO).
Is Beijing Scitop Bio-Tech expensive compared with its peers?
On forward p/e it trades at 21.5× against a peer median of 17.9×, 3rd most expensive of 6 in its peer set.
How has Beijing Scitop Bio-Tech stock performed?
Over six months to 18 Nov 2026 the shares returned -28.3% against -5.6% for the median peer; over one year -27.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.